• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 162

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action

Ayahuasca Podcast: Joe Moore – Safe Access, Breathwork and Building a Psychedelic Informed World

In Aspen, a Bipartisan Strategy for Ibogaine Takes Shape as Advocates Confront the Limits of Traditional Rehab

Genesee Herzberg — Ketamine Truths, MDMA Hopes, and the Work of Integration

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

PT332 – James Lanthier – Patentability, Capitalism, and The Next Generation...

Incannex to Present at the H.C. Wainwright First Annual Mental Health...

Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping...

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st...

Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration...

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

CB Therapeutics granted a new patent that will help further provide...

Wake Network, Inc. Receives Certificate of Drug Registration for Microdose Formulation...

Diamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of...

Gilgamesh Announces Clinical Candidates For Two Programs With First In Human...

1...161162163...301Page 162 of 301

EDITOR PICKS

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action

Ayahuasca Podcast: Joe Moore – Safe Access, Breathwork and Building a...

In Aspen, a Bipartisan Strategy for Ibogaine Takes Shape as Advocates...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©